Financial Performance - Net revenues for the three months ended March 31, 2025, were $579,655, down 30.1% from $829,029 in the same period of 2024[13]. - The net loss for the first quarter of 2025 was $1,038,011, compared to a net loss of $282,326 in Q1 2024, indicating a substantial increase in losses[13]. - The Company reported a loss per common share of $0.17 for Q1 2025, compared to $0.06 for Q1 2024[13]. - Patient care services revenue was $570,936 for the three months ended March 31, 2025, down from $785,843 in 2024, reflecting a decline of 27.3%[28]. - The Company reported $85,273 in reimbursements from insurance payers for the three months ended March 31, 2025, representing a 145.6% increase from $34,772 in 2024[29]. Assets and Liabilities - Total assets decreased from $3,677,992 to $2,563,591, a decline of approximately 30.3%[11]. - Total stockholders' equity fell from $2,568,310 to $1,529,050, a decrease of about 40.5%[11]. - Total liabilities decreased to $1,034,541 as of March 31, 2025, down 6.8% from $1,109,682 at December 31, 2024[11]. - Total property and equipment, net, decreased to $105,184 as of March 31, 2025, from $122,955 as of December 31, 2024, reflecting a decline of 13.0%[30]. Operating Expenses - Operating expenses increased significantly to $1,621,396, compared to $1,066,156, representing a 52% increase year-over-year[13]. - The company incurred $1,621,396 in total operating expenses, with salaries and wages accounting for $1,003,177, which is 61.8% of total operating expenses[13]. - Operating lease expense for the three months ended March 31, 2025, was $52,356, an increase from $34,642 in 2024[32]. - Total lease expense for the three months ended March 31, 2025, was $55,828, an increase of 58.5% from $35,289 in 2024[32]. - Stock-based compensation expense was $8,308 for the three months ended March 31, 2025, compared to $7,616 in 2024, reflecting an increase of 9.1%[42]. Cash Flow - Cash and cash equivalents decreased from $2,273,624 at the end of 2024 to $1,140,574, a reduction of approximately 50.1%[19]. - The company utilized $865,083 in cash from operating activities during the first quarter of 2025, compared to $213,439 in Q1 2024[19]. - The company reported a net cash used in operating activities of $865,083 for Q1 2025, compared to $213,439 for Q1 2024, indicating increased cash outflow[19]. Capital Expenditures - Capitalized software additions amounted to $173,448 in Q1 2025, indicating ongoing investment in technology[19]. - Capitalized software increased to $561,786 as of March 31, 2025, compared to $388,338 as of December 31, 2024, marking a growth of 44.5%[31]. Shareholder Actions - The Company repurchased 7,500 shares in treasury at a cost of $9,557 during the three months ended March 31, 2025[40]. - The company repurchased 7,500 shares of treasury stock, increasing the total treasury stock to $31,702 as of March 31, 2025[16]. - The weighted-average number of shares outstanding increased to 6,024,980 for Q1 2025, compared to 4,617,798 for Q1 2024[13]. Other Information - There were no material subsequent events that require disclosure as of the date of this filing[44]. - Total finance lease liabilities as of March 31, 2025, were $9,141, down from $9,645 as of December 31, 2024[35]. - As of March 31, 2025, the Company had 2,862,745 potential common share equivalents from stock options and warrants excluded from diluted loss per share calculations due to their anti-dilutive effect[39].

Financial Performance - The company reported revenues of $2,719,840 for the year ended December 31, 2024, a decrease of $1,048,758, or 27.8%, compared to $3,768,598 for the year ended December 31, 2023[210]. - Loss from operations was $(3,346,771), or (123.1)%, for the year ended December 31, 2024, compared to $(1,620,220), or (43.0)%, for the year ended December 31, 2023[208]. - The company reported a net loss of $(3,617,647), or (133.0)%, for the year ended December 31, 2024, compared to $(1,617,461), or (42.9)%, for the year ended December 31, 2023[208]. - Net loss increased to $3,617,647 for the year ended December 31, 2024, compared to $1,617,461 in 2023, with net loss per share rising by $0.31 or 86.7% to $(0.67)[2]. Operating Expenses - Operating expenses increased by $677,793, or 12.6%, to $6,066,611 for the year ended December 31, 2024, from $5,388,818 for the year ended December 31, 2023[211]. - General and administrative expenses increased by $551,007, or 40.6%, to $1,907,055, mainly due to increased professional fees and insurance expenses[1]. - Salaries and wages decreased by $136,062, or 3.7%, to $3,562,405 for the year ended December 31, 2024, primarily due to $351,833 less contract labor[1]. Revenue Sources - The company recognized $347,633 in reimbursements from insurance payers for the twelve months ended December 31, 2024, representing a 1,088% increase compared to $29,265 for the same period in 2023[209]. - Cost of revenues was $82,814, or 3.0% of revenues, for the year ended December 31, 2024, compared to $226,166, or 6.0% of revenues, for the year ended December 31, 2023[208]. - Cost of revenues decreased by $143,352, or 63.4%, to $82,814, due to the elimination of white-labeled retail products[1]. Research and Development - Research and development expenses increased to $377,731, or 13.9% of revenues, for the year ended December 31, 2024, from $2,500, or 0.1% of revenues, for the year ended December 31, 2023[208]. - Research and development expenses surged by $375,231, or 15,009.2%, to $377,731, attributed to the development of Enterprise Data Management infrastructure[1]. Cash Flow and Capital - Cash used in operating activities was $3,073,891, compared to $449,489 in 2023, primarily due to the increase in net loss[6]. - Cash provided by financing activities was $5,223,646, significantly up from $802,491 in 2023, mainly due to net proceeds from the issuance of common shares[7]. - Working capital increased by $2,097,122, or 1,061.7%, to $1,899,602, primarily due to $5.9 million in net proceeds from the IPO[3]. - Total assets rose by $2,578,790, or 234.6%, to $3,677,992, driven by increases in cash and cash equivalents, right of use assets, and capitalized software[4]. - Total liabilities decreased by $97,932, or 8.1%, to $1,109,682, mainly due to a reduction in derivative liability and notes payable[5]. Strategic Initiatives - The company aims to expand in-network insurance contracts to enhance future revenue growth opportunities[210]. - The company discontinued white-labeled product sales in 2024, contributing to the decrease in retail sales[210].

Financial Performance - Total revenues for the three months ended September 30, 2024, were $647,867, a decrease of 25.4% compared to $869,268 for the same period in 2023[8]. - Operating expenses for the three months ended September 30, 2024, were $1,697,685, an increase of 22.9% from $1,380,865 in the prior year[8]. - Net loss for the three months ended September 30, 2024, was $1,014,147, compared to a net loss of $515,146 for the same period in 2023, representing a 96.8% increase in losses[8]. - Revenues for Q3 2024 were $647,867, a decrease of 25.5% compared to $869,268 in Q3 2023[8]. - Total operating expenses increased to $1,697,685 in Q3 2024, up 23% from $1,380,865 in Q3 2023[8]. - Net loss for Q3 2024 was $1,014,147, compared to a net loss of $515,146 in Q3 2023, representing a 96.8% increase in losses[8]. - The company reported a net loss of $2,616,126 for the nine months ended September 30, 2024, compared to a net loss of $1,292,533 for the same period in 2023, indicating a 102.5% increase in losses[8]. Cash and Liquidity - Cash and cash equivalents increased significantly to $3,642,944 as of September 30, 2024, compared to $525,500 at the end of 2023[6]. - The company completed an initial public offering (IPO) on June 3, 2024, generating total net proceeds of $5,860,650, which is expected to provide adequate liquidity for at least the next 12 months[23]. - The company reported total working capital of $3,215,466 as of September 30, 2024[22]. - The company had cash and cash equivalents of $3,642,944 as of September 30, 2024, compared to $151,245 at the end of the same period in 2023[22]. Assets and Liabilities - Total assets rose to $4,324,162 as of September 30, 2024, up from $1,099,202 at December 31, 2023[6]. - Total liabilities decreased to $840,107 as of September 30, 2024, from $1,207,614 at December 31, 2023[6]. - Current liabilities decreased to $725,867 as of September 30, 2024, from $814,448 as of December 31, 2023[6]. - Total inventories as of September 30, 2024, were $2,750, significantly down from $125,202 as of December 31, 2023[30]. - Total property and equipment, net, as of September 30, 2024, was $183,349, a decrease from $235,292 as of December 31, 2023[31]. - Operating lease liabilities totaled $207,096 as of September 30, 2024, down from $258,991 as of December 31, 2023[33]. Stock and Equity - Stockholders' equity improved to $3,484,055 as of September 30, 2024, compared to a deficit of $(108,412) at the end of 2023[6]. - The company had 5,977,476 common shares issued and outstanding as of September 30, 2024, compared to 4,617,798 as of December 31, 2023[45]. - The company approved a Stock Repurchase Program on October 15, 2024, allowing for the purchase of up to $500,000 worth of its common stock[65]. - The company issued 1,240,910 common shares in connection with a public offering, raising $5,860,650[12]. Compensation and Expenses - The company experienced a significant increase in salaries and wages, totaling $1,138,561 for the three months ended September 30, 2024, compared to $995,078 in the same period of 2023, reflecting a 14.4% increase[8]. - Stock-based compensation for the nine months ended September 30, 2024, was $132,994, a decrease from $719,169 in the same period of 2023[17]. - The company recorded stock-based compensation expenses of $72,508 and $88,008 for the three and nine months ended September 30, 2024, respectively[61]. Operational Activities - The company utilized cash flows in operating activities amounting to $2,172,361 for the nine months ended September 30, 2024[22]. - Cash flows used in operating activities for the nine months ended September 30, 2024, were $2,172,361, significantly higher than $240,806 in the same period of 2023[17]. - The company incurred an operating loss of $2,324,138 for the nine months ended September 30, 2024[22]. Other Income and Reimbursements - The company earned $106,567 in reimbursements from insurance payers during the three months ended September 30, 2024, representing a 16.4% increase compared to $91,553 in the previous quarter[29]. - The company earned $232,842 in reimbursements from insurance payers during the nine months ended September 30, 2024, compared to $0 in the same period of 2023[29]. - Other income for Q3 2024 was $45,330, significantly higher than $9,001 in Q3 2023[8].

Financial Performance - Total revenues for Q2 2024 were $639,057, a decrease of 34.8% compared to $979,538 in Q2 2023[9] - Operating expenses for Q2 2024 totaled $1,676,250, an increase of 6.0% from $1,580,827 in Q2 2023[9] - Net loss for Q2 2024 was $1,319,653, compared to a net loss of $596,408 in Q2 2023, representing a 121.5% increase in losses[9] - Loss per common share for Q2 2024 was $(0.26), compared to $(0.13) in Q2 2023[9] - Total operating expenses for the six months ended June 30, 2024, were $2,742,406, a decrease of 6.9% from $2,946,377 in the same period of 2023[9] - For the six months ended June 30, 2024, the company incurred a net loss of $1,601,979, compared to a net loss of $777,387 for the same period in 2023[12] - The company incurred an operating loss of $1,274,320 for the six months ended June 30, 2024[18] Cash and Liquidity - Cash and cash equivalents increased significantly to $4,740,006 as of June 30, 2024, compared to $525,500 at the end of 2023[7] - The company reported cash and cash equivalents of $4,740,006 and total working capital of $4,111,725 as of June 30, 2024[18] - The company raised $5.86 million in net proceeds from its initial public offering (IPO) completed on June 3, 2024, providing adequate liquidity for at least the next 12 months[19] - The company reported a cash balance of $4,740,006 at the end of Q2 2024, up from $525,500 at the beginning of the period[12] Assets and Liabilities - Total assets rose to $5,456,937 as of June 30, 2024, up from $1,099,202 at the end of 2023[7] - Current liabilities increased to $942,943 as of June 30, 2024, compared to $814,448 at the end of 2023, reflecting a 15.7% rise[7] - Total inventories as of June 30, 2024, were $3,825, significantly down from $125,202 as of December 31, 2023[22] - Total property and equipment, net, decreased to $206,816 as of June 30, 2024, from $235,292 as of December 31, 2023[23] - Operating lease liabilities totaled $204,624 as of June 30, 2024, down from $258,991 at the end of 2023[24] Stockholders' Equity - Stockholders' equity improved to $4,380,708 as of June 30, 2024, compared to a deficit of $(108,412) at the end of 2023[7] - The company’s total stockholders' equity (deficit) as of June 30, 2024, was $4,380,708, compared to a deficit of $58,352 as of June 30, 2023[11] - Total stockholders' equity as of June 30, 2024, was $4,380,708, an increase from $(383,122) at the end of Q1 2024[11] Initial Public Offering (IPO) - The initial public offering (IPO) was completed on June 3, 2024, with 1,240,910 units sold at a public price of $5.50 per share[36] - The IPO completed on June 3, 2024, resulted in gross proceeds of approximately $6.8 million and net proceeds of approximately $5.9 million after deducting expenses[38] - The company issued 1,240,910 units in the IPO, each consisting of one share of common stock and one tradeable warrant with an exercise price of $6.33[45] Stock-Based Compensation - Stock-based compensation for the six months ended June 30, 2024, was $15,500, a decrease from $338,021 in the same period of 2023[12] - Stock-based compensation expense recorded during the three and six months ended June 30, 2024, was $7,884 and $15,500, respectively[44] - The company granted stock options to purchase 5,590 shares of common stock at an exercise price of $5.50, with an estimated fair market value of $15,500[42] Other Financial Activities - The company used cash flows in operating activities of $1,126,976 for the six months ended June 30, 2024, compared to $274,964 for the same period in 2023[12] - The company reported a net cash provided by financing activities of $5,352,664 for the six months ended June 30, 2024[12] - The company extinguished its derivative liability upon settlement of notes payable, resulting in a loss on extinguishment of debt of $38,889[32]

Financial Performance - Total revenues for Q1 2024 were $829,029, a decrease of 28.5% compared to $1,160,345 in Q1 2023[8] - Net loss for Q1 2024 was $282,326, compared to a net loss of $180,979 in Q1 2023, representing a 56.0% increase in losses[8] - Loss per common share for Q1 2024 was $0.06, compared to $0.04 in Q1 2023[8] - Revenues decreased by $331,316, or 28.6%, to $829,029 for the three months ended March 31, 2024, compared to $1,160,345 for the same period in 2023[59] - Net loss was $282,326 for the three months ended March 31, 2024, compared to $180,979 for the same period in 2023, representing a net loss increase of 56.0%[64] Operating Expenses - Operating expenses for Q1 2024 totaled $1,066,156, a decrease of 21.9% from $1,365,550 in Q1 2023[8] - Operating expenses decreased by $299,394, or 21.9%, to $1,066,156 for the three months ended March 31, 2024, from $1,365,550 for the same period in 2023[61] - Total operating expenses as a percentage of revenues increased to 128.6% for the three months ended March 31, 2024, compared to 117.7% for the same period in 2023[58] - Salaries and wages decreased by $225,335, or 24.1%, to $707,966 for the three months ended March 31, 2024, due to reduced need for employee and contract labor[61] - General and administrative expenses decreased by $32,638, or 9.1%, to $325,545 for the three months ended March 31, 2024, attributed to lower marketing and advertising spending[61] - Cost of revenues decreased by $40,880, or 84.1%, to $7,744 for the three months ended March 31, 2024, due to a decline in product revenues[61] Cash and Assets - Cash and cash equivalents decreased to $287,383 as of March 31, 2024, down 45.2% from $525,500 as of December 31, 2023[7] - Total current assets decreased to $356,019 as of March 31, 2024, down 42.3% from $616,928 as of December 31, 2023[7] - The company reported a total working capital deficit of $505,419 as of March 31, 2024[15] - Cash and cash equivalents as of March 31, 2024, were $287,383, down from $525,500 as of December 31, 2023, reflecting a decrease of $238,117, or 45.3%[69] - Total inventories, net, as of March 31, 2024, were $55,872, down from $63,202 at December 31, 2023[19] Liabilities and Equity - Total liabilities decreased to $1,182,437 as of March 31, 2024, down 2.1% from $1,207,614 as of December 31, 2023[7] - Total stockholders' deficit increased to $383,122 as of March 31, 2024, compared to $108,412 as of December 31, 2023[7] - The accumulated deficit increased to $(4,440,380) as of March 31, 2024, compared to $(4,158,054) at December 31, 2023[9] - The company reported a weighted-average number of shares outstanding of 4,617,798 for Q1 2024, compared to 4,434,596 for Q1 2023, an increase of 4.1%[8] Initial Public Offering (IPO) - The company completed an initial public offering (IPO) on June 3, 2024, raising total net proceeds of $6.02 million[16] - The IPO completed on June 3, 2024, resulted in gross proceeds of approximately $6.8 million and net proceeds of approximately $6.0 million after deducting expenses[56] - The company repaid all outstanding 10% OID promissory notes totaling $463,534 and issued 80,808 shares of restricted common stock at the IPO price of $5.50 per share[40] Insurance and Revenue Sources - Patient care services revenue for the three months ended March 31, 2024, was $785,843, down from $1,067,955 in 2023, representing a decline of 26.4%[18] - The company recognized $34,722 in reimbursements from insurance payers during the three months ended March 31, 2024, compared to $0 in the same period of 2023[18] - The company is shifting to insurance billing with commercial and governmental payers, impacting cash-pay patient care services[59] Strategic Initiatives - The company aims to reduce opioid use through an integrated model of prescriber and therapist teams, focusing on evidence-based behavioral therapy and non-opioid alternatives[45] - The company has established a medical advisory committee to evaluate the efficacy of care programs and set impact goals against national benchmarks[49] - The company is actively involved in the Biden-Harris opioid initiative, emphasizing decreased overprescribing and improved access to addiction treatment[48] Other Financial Metrics - Interest expense was $57,239 for the three months ended March 31, 2024, primarily due to accrued interest and amortization of debt discounts[63] - Other income decreased by $12,186, or 50.3%, to $12,040 for the three months ended March 31, 2024, from $24,226 for the same period in 2023[62] - The company incurred cash flows used in operating activities of $213,439 for the three months ended March 31, 2024, compared to cash flows provided by operating activities of $167,100 for the same period in 2023[69]